Grade III or IV surgical complications, as assessed by the Clavien–Dindo classification, occurred in 29% (N = 5) of patients, which included a non-ST elevated myocardial infarction (managed with stent placement), sepsis, and cellulitis (managed successfully with antibiotics), and acute respiratory failure (managed uneventfully), none of which were attributed to anti-OX40 administration (Supplementary Table 3). The gene discussed is TNFRSF4; the disease is cellulitis.